Insider Buying: A Smart Investment Strategy

by Fred Fuld III

When investors look for a “buy” signal, they often turn to the people who know the company best: its own executives and board members. While analysts look at balance sheets from the outside, insiders see the daily operations, upcoming contracts, and cultural shifts that won’t hit a public report for months.

As legendary fund manager Peter Lynch famously noted: “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.”

The Advantages of Following “Skin in the Game”

Buying stocks with strong insider activity offers several distinct strategic benefits:

  • Asymmetric Information: Insiders have an “information advantage.” They understand the nuances of their industry’s cycle and can identify when the market has overreacted to temporary bad news.
  • Alignment of Interests: When a CEO buys a significant amount of stock with their own cash, their personal wealth becomes tied to the stock price. This aligns their incentives with those of retail shareholders.
  • Signaling Undervaluation: Heavy insider buying often occurs when a stock is “beaten down.” It serves as a loud signal from management that they believe the current market price does not reflect the company’s intrinsic value.
  • Predictive Power in Small Caps: Historical data suggests that insider buying is particularly predictive in small-cap and mid-cap stocks, where fewer Wall Street analysts are providing coverage.

Companies with Recent Strong Insider Activity

Here are four companies that have seen notable insider conviction as of early 2026.

Asbury Automotive (ABG)

Asbury Automotive is one of the largest automotive retailers in the United States, operating a vast network of dealerships and service centers. With a market cap of approximately $4.81 billion, the company currently trades at a relatively low P/E ratio of 8.63. While Asbury does not pay a regular dividend, it has been aggressive in its share repurchase programs.

  • Recent Activity: Over the last 12 months, the company has seen notable conviction from institutional insiders, including a massive purchase of roughly $10.6 million (46,952 shares) by Abrams Capital Management. While there has been some selling by officers for tax and compensation purposes (roughly 22,000 shares in the last year), the net volume of shares bought on the open market remains significantly higher than those sold.

Anterix (ATEX)

Anterix is a specialized telecommunications company focused on providing private LTE network solutions, particularly for the utility sector. It has a market cap of roughly $475 million and a P/E ratio of 5.11. The company currently does not offer a dividend.

  • Recent Activity: Insider sentiment at Anterix has been overwhelmingly positive. In late 2025, CEO Scott Lang made multiple open-market purchases totaling over $170,000. Overall, in the most recent 100 recorded trades, insiders have purchased roughly 2.44 million shares compared to only 307,000 shares sold, indicating a heavy bias toward the “buy” side as the company hits new operational milestones.

Universal Safety (UUU)

Universal Safety Products is a micro-cap player in the safety technology space, known for its smoke and carbon monoxide detection systems. The company has a market cap of $11.5 million and trades at a very low P/E ratio of 4.0. In late 2025, the company made headlines by paying a significant one-time special dividend of $1.00 per share following a successful asset sale.

  • Recent Activity: Director Milton Ault III has been on a buying spree throughout the end of 2025. In December alone, he executed nearly a dozen separate purchases, totaling hundreds of thousands of dollars. Within the last three months, insiders have bought over 108,000 shares while recording zero sales, a rare “clean” signal of management confidence.

WW International (WW)

Commonly known as WeightWatchers, WW International is currently navigating a major business pivot toward the clinical weight-loss and GLP-1 medication space. It has a market cap of approximately $236 million. Its P/E ratio has been volatile due to recent losses but is currently projected at roughly 13.0 for future earnings. The company does not currently pay a dividend.

  • Recent Activity: Despite a challenging stock price environment, insiders are stepping in. Director Carney Hawks recently purchased 29,057 shares at an average price of $22.14, a total investment of over $643,000. This purchase significantly outweighed the minor selling of 469 shares by the company’s controller during the same period, suggesting that the board sees a disconnect between the current price and the company’s long-term pivot.

The Verdict on Insider Signals

When you look at the raw numbers, a pattern emerges: for these four companies, the volume of shares being purchased by insiders significantly exceeds the volume being sold. In the case of Universal Safety, the signal is a “unanimous” buy with zero selling. For Anterix and WW International, the sheer dollar amount of the recent buys suggests that leadership is willing to back their turnaround strategies with their own personal wealth.

Disclosure: Author didn’t own any of the above at the time the article was written. No recommendations are expressed or implied.

Can Weight Loss Companies Fuel Gains in Your Stock Portfolio?

by Fred Fuld III

The past year has seen a surge in the popularity of injectable medications for weight loss. Drugs like Ozempic and Wegovy, both made by Novo Nordisk (NVO), and Zepbound and Mounjaro, which are manufactured by Eli Lilly (LLY), are finding themselves in high demand, despite their hefty price tags and limited insurance coverage.

This trend reflects a growing openness to pharmaceutical solutions for weight management, alongside traditional methods like diet and exercise. These injectable drugs, which mimic natural gut hormones, work by curbing appetite and promoting feelings of fullness. Studies have shown significant weight loss in patients using these medications.

Ozempic and Wegovy are both GLP-1 receptor agonists, targeting a specific hormone that regulates appetite and blood sugar. Ozempic was originally approved for type 2 diabetes, but its weight loss side effects have driven its use in that area as well. Wegovy, on the other hand, is specifically FDA-approved for chronic weight management.

Zepbound, a newcomer to the market, is another GLP-1 receptor agonist with an additional twist. It also targets another gut hormone, GIP, that further enhances feelings of fullness and reduces appetite. Early studies suggest Zepbound may lead to even greater weight loss than Wegovy.

Mounjaro, another Eli Lilly product, joins the party as a dualincretin medication. Like Zepbound, it targets both GLP-1 and GIP receptors, offering similar weight loss benefits. Interestingly, Mounjaro is actually FDA-approved for type 2 diabetes, but like Ozempic, its weight loss effects are driving its use in that area as well. Studies suggest Mounjaro might be as effective as Zepbound in terms of weight loss.

This rise in weight loss injectable use is projected to continue. Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain. The high cost and limited insurance coverage are barriers for many. Additionally, long-term side effects of these medications are still being studied.

While these injectable drugs offer a promising new tool for weight management, they are not a magic bullet. They are most effective when used in conjunction with a healthy diet and exercise program.

Novo Nordisk (NVO) is a global healthcare company headquartered near Copenhagen, Denmark, with a rich history dating back to 1923. Their founding story is intertwined with the discovery of insulin, a revolutionary treatment for diabetes.

The company’s mission is “to drive change to defeat serious chronic diseases,” and they have become a leader in the diabetes care space. They develop and manufacture a wide range of diabetes medications, including injectable insulins and GLP-1 receptor agonists like the popular Ozempic and Wegovy mentioned earlier.

Beyond diabetes, Novo Nordisk is expanding its reach into other chronic diseases. They offer treatments for obesity, such as Wegovy, and medications for hemophilia and other rare blood disorders. Their research and development efforts continue to push boundaries in these areas.

    Novo Nordisk employs over 64,000 people worldwide and distributes its products in over 170 countries.

    The stock trades at 44 times trailing earnings and 31 time forward earnings. Quarterly revenue growth year-over-year was 23.6%, with earning growth over the same period at an incredible 30.7%.

    Novo pays a dividend semi-annually, with an estimated yield of 1.31%.

    Eli Lilly and Company (LLY), headquartered in Indianapolis, Indiana, boasts a rich heritage dating back to 1876. Founded by Colonel Eli Lilly with a vision to “take what you find here and make it better and better,” the company has established itself as a major player in the pharmaceutical industry.

    Eli Lilly is dedicated to turning science into solutions for a healthier world. Their core focus lies in research and development, with a significant portion of their workforce dedicated to this pursuit. They leverage advancements in biotechnology, chemistry, and genetic medicine to tackle some of the world’s most pressing health challenges.

    The company’s product portfolio is extensive, encompassing medications for a wide range of conditions. Here’s a glimpse into their key areas:

    • Diabetes: Eli Lilly has a strong presence in diabetes care, offering medications beyond the newcomer, Mounjaro,discussed earlier.
    • Oncology: They are actively involved in cancer research and development, producing treatments for various types of cancer.
    • Immunology: Eli Lilly develops medications for autoimmune diseases and other conditions related to the immune system.
    • Pain Management: The company offers a range of pain management solutions.
    • Others: Eli Lilly’s product line also includes medications for neurology, endocrinology, and other therapeutic areas.

    With over 44,000 employees worldwide and a strong emphasis on scientific advancement, Eli Lilly remains a force to be reckoned with in the global pharmaceutical landscape.

    Lilly has a nosebleed high trailing price to earnings ratio of 116; but a bit more reasonable forward P/E of 41.5. Quarterly revenue growth grew 26%, with quarterly earnings per share growth at a superior 66.7% year-over-year.

    The company pays dividends quarterly and yields 0.67%.

    If you are looking for a non-pharmaceutical investment option, there is WW International (WW).

    WW International, Inc., formerly known as Weight Watchers International, is a global company headquartered in New York City. Founded in 1963 by Jean Nidetch, WW has a long history of helping people achieve weight loss and wellness goals.

    Shifting Focus: Beyond Weight Loss

    Traditionally, WW was known for its weight loss programs, often centered around group meetings and a points-based system for tracking food intake. However, in 2018, the company underwent a significant rebranding, reflecting a shift towards a more holistic approach to health and wellness.

    This move is reflected in their new name, WW, which purposely avoids mentioning weight. Their current programs encompass aspects like fitness, mindset, and overall healthy habits, not just weight loss on the scale.

    WW’s Offerings Today

    WW offers a multi-pronged approach to wellness, with options to suit different needs and preferences:

    • Digital Solutions: Their mobile app and website provide access to tools for tracking food, activity, weight, and sleep. They also offer educational content and motivational support.
    • Coaching: WW provides online or phone coaching for personalized guidance and support.
    • Wellness Workshops: These in-person group meetings, formerly known as Weight Watchers meetings, foster a sense of community and offer guidance on healthy living.

    Financial Performance

    While they have faced challenges in recent years, they remain a major player in the weight management and wellness industry.

    The stock has taken a major hit in the last seven months, dropping from above $13 a share to now less than two dollars a share.

    The company generated a huge lost for the year; however, it is estimated that it will produce a reasonable profit next year, providing a forward P/E of 7.06.

    Summary

    Novo and Lilly have already had major gains in their stock price. It remains to be seen it this growth will continue, especially with greater acceptance of their drugs.

    Hopefully, one of these companies can provide greater weight to your portfolio.

    Disclosure: Author has a small bullish call position in Novo.